Abstract
Peroxisome proliferator-activated receptor gamma (PPARγ) has been implicated in the pathology of numerous diseases involving diabetes, stroke, cancer, or obesity. It is expressed in diverse cell types, including vessels, immune and glial cells, and neurons. PPARγ plays crucial roles in the regulation of cellular differentiation, lipid metabolism, or glucose homeostasis. PPARγ ligands also exert effects on attenuating degenerative processes in the brain, as well as in peripheral systems, and it has been associated with the control of anti-inflammatory mechanisms, oxidative stress, neuronal death, neurogenesis, differentiation, and angiogenesis. This review will highlight key advances in the understanding of the PPARγ-related mechanisms responsible for neuroprotection after brain injuries, both ischemia and traumatic brain injury, and it will also cover the natural and synthetic agonist for PPARγ, angiotensin receptor blockers, and PPARγ antagonists, used in experimental and clinical research. A better understanding of the pleiotropic mechanisms and applications of these drugs to improve the recovery and to repair the acute and chronic induced neuroinflammation after brain injuries will pave the way for more effective therapeutic strategies after brain deficits.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdelrahman M, Sivarajah A, Thiemermann C (2005) Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 65:772–781. doi:10.1016/j.cardiores.2004.12.008
Akiyama TE, Meinke PT, Berger JP (2005) PPAR ligands: potential therapies for metabolic syndrome. Curr Diabetes Rep 5:45–52
Angelakis E et al (2012) An evaluation of the effects of Lactobacillus ingluviei on body weight, the intestinal microbiome and metabolism in mice. Microb Pathog 52:61–68. doi:10.1016/j.micpath.2011.10.004
Annabi B, Lord-Dufour S, Vezina A, Beliveau R (2012) Resveratrol targeting of carcinogen-induced brain endothelial cell inflammation biomarkers MMP-9 and COX-2 is Sirt1-independent. Drug Target Insights 6:1–11. doi:10.4137/DTI.S9442
Arai K, Jin G, Navaratna D, Lo EH (2009) Brain angiogenesis in developmental and pathological processes: neurovascular injury and angiogenic recovery after stroke. FEBS J 276:4644–4652. doi:10.1111/j.1742-4658.2009.07176.x
Arany Z et al (2008) HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 451:1008–1012. doi:10.1038/nature06613
Aronowski J, Zhao X (2011) Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke 42:1781–1786. doi:10.1161/STROKEAHA.110.596718
Ballesteros I et al (2014) Rosiglitazone-induced CD36 up-regulation resolves inflammation by PPARgamma and 5-LO-dependent pathways. J Leukoc Biol 95:587–598. doi:10.1189/jlb.0613326
Behl T, Kaur I, Goel H, Kotwani A (2016) Implications of the endogenous PPAR-gamma ligand, 15-deoxy-delta-12, 14-prostaglandin J2, in diabetic retinopathy. Life Sci 153:93–99. doi:10.1016/j.lfs.2016.03.054
Berger JP, Akiyama TE, Meinke PT (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26:244–251. doi:10.1016/j.tips.2005.03.003
Bernardo A, Minghetti L (2006) PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 12:93–109
Bernardo A, Minghetti L (2008) Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists. PPAR Res 2008:864140. doi:10.1155/2008/864140
Blaschke F, Caglayan E, Hsueh WA (2006a) Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes. Endocrinol Metab Clin N Am 35:561–574. doi:10.1016/j.ecl.2006.06.001
Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA (2006b) Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol 26:28–40. doi:10.1161/01.ATV.0000191663.12164.77
Bouhlel MA et al (2007) PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 6:137–143. doi:10.1016/j.cmet.2007.06.010
Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC (2002) Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson’s disease. J Neurochem 82:615–624
Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI (2003) Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 43:252–259
Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM (2001) PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:48–52. doi:10.1038/83336
Chu K et al (2006) Peroxisome proliferator-activated receptor-gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia. Brain Res 1093:208–218. doi:10.1016/j.brainres.2006.03.114
Cimini A, Ceru MP (2008) Emerging roles of peroxisome proliferator-activated receptors (PPARs) in the regulation of neural stem cells proliferation and differentiation. Stem Cell Rev 4:293–303. doi:10.1007/s12015-008-9024-2
Collin M, Murch O, Thiemermann C (2006) Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia. Crit Care Med 34:1131–1138. doi:10.1097/01.CCM.0000206472.63040.6D
Collino M et al (2006) Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 530:70–80. doi:10.1016/j.ejphar.2005.11.049
Collino M, Patel NS, Thiemermann C (2008) PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury Ther Adv. Cardiovasc Dis 2:179–197. doi:10.1177/1753944708090924
Couvigny B et al (2015) Commensal Streptococcus salivarius modulates PPARgamma transcriptional activity in human intestinal epithelial cells. PLoS ONE 10:e0125371. doi:10.1371/journal.pone.0125371
Culman J, Zhao Y, Gohlke P, Herdegen T (2007) PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol Sci 28:244–249. doi:10.1016/j.tips.2007.03.004
Delerive P, Fruchart JC, Staels B (2001) Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169:453–459
Dunning S et al (2013) Glutathione and antioxidant enzymes serve complementary roles in protecting activated hepatic stellate cells against hydrogen peroxide-induced cell death. Biochim Biophys Acta 1832:2027–2034. doi:10.1016/j.bbadis.2013.07.008
Ehrmann J Jr, Vavrusova N, Collan Y, Kolar Z (2002) Peroxisome proliferator-activated receptors (PPARs) in health and disease. Biomed Pap 146:11–14
Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage FH (1998) Neurogenesis in the adult human hippocampus. Nat Med 4:1313–1317. doi:10.1038/3305
Eslami H, Sharifi AM, Rahimi H, Rahati M (2014) Protective effect of telmisartan against oxidative damage induced by high glucose in neuronal PC12 cell. Neurosci Lett 558:31–36. doi:10.1016/j.neulet.2013.10.057
Esposito G et al (2011) Cannabidiol reduces Abeta-induced neuroinflammation and promotes hippocampal neurogenesis through PPARgamma involvement. PLoS ONE 6:e28668. doi:10.1371/journal.pone.0028668
Garcia-Bueno B, Caso JR, Perez-Nievas BG, Lorenzo P, Leza JC (2007) Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats. Neuropsychopharmacology 32:1251–1260. doi:10.1038/sj.npp.1301252
Gemma C, Stellwagen H, Fister M, Coultrap SJ, Mesches MH, Browning MD, Bickford PC (2004) Rosiglitazone improves contextual fear conditioning in aged rats. NeuroReport 15:2255–2259
Giannini S, Serio M, Galli A (2004) Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 27:982–991. doi:10.1007/BF03347546
Griggs RB, Yermakov LM, Susuki K (2017) Formation and disruption of functional domains in myelinated CNS axons. Neurosci Res 116:77–87. doi:10.1016/j.neures.2016.09.010
Gurley C, Nichols J, Liu S, Phulwani NK, Esen N, Kielian T (2008) Microglia and astrocyte activation by toll-like receptor ligands: modulation by PPAR-gamma agonists. PPAR Res 2008:453120. doi:10.1155/2008/453120
Han L et al (2015) Rosiglitazone promotes white matter integrity and long-term functional recovery after focal cerebral ischemia. Stroke 46:2628–2636. doi:10.1161/STROKEAHA.115.010091
Heald M, Cawthorne MA (2011) Dual acting and pan-PPAR activators as potential anti-diabetic therapies. Handb Exp Pharmacol. doi:10.1007/978-3-642-17214-4_2
Hegarty BD, Furler SM, Oakes ND, Kraegen EW, Cooney GJ (2004) Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo—a study using the novel PPARalpha/gamma agonist tesaglitazar. Endocrinology 145:3158–3164. doi:10.1210/en.2004-0260
Heneka MT, Landreth GE (2007) PPARs in the brain. Biochim Biophys Acta 1771:1031–1045. doi:10.1016/j.bbalip.2007.04.016
Heneka MT, Klockgether T, Feinstein DL (2000) Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20:6862–6867
Iruretagoyena MI et al (2006) Inhibition of nuclear factor-kappa B enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 318:59–67. doi:10.1124/jpet.106.103259
Ji S, Kronenberg G, Balkaya M, Farber K, Gertz K, Kettenmann H, Endres M (2009) Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome. Exp Neurol 216:321–328. doi:10.1016/j.expneurol.2008.12.007
Jung KH et al (2007) Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther 322:1051–1058. doi:10.1124/jpet.107.120097
Kapadia R, Yi JH, Vemuganti R (2008) Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 13:1813–1826
Karrout Y et al (2015) In vivo efficacy of microbiota-sensitive coatings for colon targeting: a promising tool for IBD therapy. J Control Release 197:121–130. doi:10.1016/j.jconrel.2014.11.006
Kasahara Y et al (2010) Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia. Brain Res 1340:70–80. doi:10.1016/j.brainres.2010.03.101
Kaundal RK, Sharma SS (2011a) Ameliorative effects of GW1929, a nonthiazolidinedione PPARgamma agonist, on inflammation and apoptosis in focal cerebral ischemic-reperfusion injury. Curr Neurovasc Res 8:236–245
Kaundal RK, Sharma SS (2011b) GW1929: a nonthiazolidinedione PPARgamma agonist, ameliorates neurological damage in global cerebral ischemic-reperfusion injury through reduction in inflammation and DNA fragmentation. Behav Brain Res 216:606–612. doi:10.1016/j.bbr.2010.09.001
Kimura H et al (2008) A natural PPAR-gamma agonist, 15-deoxy-delta 12,14-prostaglandin J2, may act as an enhancer of PAI-1 in human proximal renal tubular cells under hypoxic and inflammatory conditions. Nephrol Dial Transplant 23:2496–2503. doi:10.1093/ndt/gfn139
Lee G et al (2002) T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem 277:19649–19657. doi:10.1074/jbc.M200743200
Lee CH, Yi MH, Chae DJ, Zhang E, Oh SH, Kim DW (2015) Effect of pioglitazone on excitotoxic neuronal damage in the mouse hippocampus. Biomol Ther 23:261–267. doi:10.4062/biomolther.2014.146 (Seoul)
Lee KC, Hsieh YC, Yang YY, Chan CC, Huang YH, Lin HC (2016) Aliskiren reduces hepatic steatosis and epididymal fat mass and increases skeletal muscle insulin sensitivity in high-fat diet-fed mice. Sci Rep 6:18899. doi:10.1038/srep18899
Lenglet S, Montecucco F, Mach F (2013) Role of matrix metalloproteinases in animal models of ischemic stroke. Curr Vasc Pharmacol 13(2):161–166
Li X, Du J, Xu S, Lin X, Ling Z (2013) Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces secondary damage in experimental spinal cord injury. J Int Med Res 41:153–161. doi:10.1177/0300060513476601
Liu X, Yu H, Yang L, Li C, Li L (2012) 15-Deoxy-Delta(12,14)-prostaglandin J(2) attenuates the biological activities of monocyte/macrophage cell lines. Eur J Cell Biol 91:654–661. doi:10.1016/j.ejcb.2012.03.004
Lozano D, Gonzales-Portillo GS, Acosta S, de la Pena I, Tajiri N, Kaneko Y, Borlongan CV (2015) Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. Neuropsychiatr Dis Treat 11:97–106. doi:10.2147/NDT.S65815
Luo Y et al (2006) Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 97:435–448. doi:10.1111/j.1471-4159.2006.03758.x
Luo Y, He Q, Kuang G, Jiang Q, Yang J (2014) PPAR-alpha and PPAR-beta expression changes in the hippocampus of rats undergoing global cerebral ischemia/reperfusion due to PPAR-gamma status. Behav Brain Funct 10:21. doi:10.1186/1744-9081-10-21
Luo W, Xu Q, Wang Q, Wu H, Hua J (2017) Effect of modulation of PPAR-gamma activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. Sci Rep 7:44612. doi:10.1038/srep44612
Maeshiba Y, Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M, Tanayama S (1997) Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 47:29–35
Mandrekar-Colucci S, Sauerbeck A, Popovich PG, McTigue DM (2013) PPAR agonists as therapeutics for CNS trauma and neurological diseases. ASN Neuro 5:e00129. doi:10.1042/AN20130030
Miglio G, Rattazzi L, Rosa AC, Fantozzi R (2009) PPARgamma stimulation promotes neurite outgrowth in SH-SY5Y human neuroblastoma cells. Neurosci Lett 454:134–138. doi:10.1016/j.neulet.2009.03.014
Moore KJ et al (2001) The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 7:41–47. doi:10.1038/83328
Morales-Garcia JA, Luna-Medina R, Alfaro-Cervello C, Cortes-Canteli M, Santos A, Garcia-Verdugo JM, Perez-Castillo A (2011) Peroxisome proliferator-activated receptor gamma ligands regulate neural stem cell proliferation and differentiation in vitro and in vivo. Glia 59:293–307. doi:10.1002/glia.21101
Moreno S, Farioli-Vecchioli S, Ceru MP (2004) Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123:131–145
Morganti-Kossmann MC, Satgunaseelan L, Bye N, Kossmann T (2007) Modulation of immune response by head injury. Injury 38:1392–1400. doi:10.1016/j.injury.2007.10.005
Mouihate A, Boisse L, Pittman QJ (2004) A novel antipyretic action of 15-deoxy-Delta 12,14-prostaglandin J2 in the rat brain. J Neurosci 24:1312–1318. doi:10.1523/JNEUROSCI.3145-03.2004
Napimoga MH, Demasi AP, Bossonaro JP, de Araujo VC, Clemente-Napimoga JT, Martinez EF (2013) Low doses of 15d-PGJ2 induce osteoblast activity in a PPAR-gamma independent manner. Int Immunopharmacol 16:131–138. doi:10.1016/j.intimp.2013.03.035
Ndubuizu OI, Tsipis CP, Li A, LaManna JC (2010) Hypoxia-inducible factor-1 (HIF-1)-independent microvascular angiogenesis in the aged rat brain. Brain Res 1366:101–109. doi:10.1016/j.brainres.2010.09.064
Nizamutdinov D, Shapiro LA (2017) Overview of traumatic brain injury: an immunological context. Brain Sci. doi:10.3390/brainsci7010011
Odegaard JI et al (2007) Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447:1116–1120. doi:10.1038/nature05894
Ormerod BK, Hanft SJ, Asokan A, Haditsch U, Lee SW, Palmer TD (2013) PPARgamma activation prevents impairments in spatial memory and neurogenesis following transient illness. Brain Behav Immun 29:28–38. doi:10.1016/j.bbi.2012.10.017
Pang T, Benicky J, Wang J, Orecna M, Sanchez-Lemus E, Saavedra JM (2012a) Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-gamma activation in human monocytes. J Hypertens 30:87–96. doi:10.1097/HJH.0b013e32834dde5f
Pang T, Wang J, Benicky J, Sanchez-Lemus E, Saavedra JM (2012b) Telmisartan directly ameliorates the neuronal inflammatory response to IL-1beta partly through the JNK/c-Jun and NADPH oxidase pathways. J Neuroinflammation 9:102. doi:10.1186/1742-2094-9-102
Park EY, Cho IJ, Kim SG (2004) Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. Cancer Res 64:3701–3713. doi:10.1158/0008-5472.CAN-03-3924
Park SW, Yi JH, Miranpuri G, Satriotomo I, Bowen K, Resnick DK, Vemuganti R (2007) Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 320:1002–1012. doi:10.1124/jpet.106.113472
Pereira MP et al (2005) The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke. J Neuropathol Exp Neurol 64:797–805
Peyrin-Biroulet L et al (2010) Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci USA 107:8772–8777. doi:10.1073/pnas.0905745107
Pilipovic K, Zupan Z, Dolenec P, Mrsic-Pelcic J, Zupan G (2015) A single dose of PPARgamma agonist pioglitazone reduces cortical oxidative damage and microglial reaction following lateral fluid percussion brain injury in rats. Prog Neuropsychopharmacol Biol Psychiatry 59:8–20. doi:10.1016/j.pnpbp.2015.01.003
Prakash A, Kumar A (2014) Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of beta-amyloid animal model of Alzheimer’s disease. Neurotox Res 25:335–347. doi:10.1007/s12640-013-9437-9
Qi L, Jacob A, Wang P, Wu R (2010) Peroxisome proliferator activated receptor-gamma and traumatic brain injury. Int J Clin Exp Med 3:283–292
Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79–82. doi:10.1038/34178
Roth AD, Leisewitz AV, Jung JE, Cassina P, Barbeito L, Inestrosa NC, Bronfman M (2003) PPAR gamma activators induce growth arrest and process extension in B12 oligodendrocyte-like cells and terminal differentiation of cultured oligodendrocytes. J Neurosci Res 72:425–435. doi:10.1002/jnr.10596
Sauerbeck A, Gao J, Readnower R, Liu M, Pauly JR, Bing G, Sullivan PG (2011) Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp Neurol 227:128–135. doi:10.1016/j.expneurol.2010.10.003
Schmerbach K et al (2008) Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain. Brain Res 1208:225–233. doi:10.1016/j.brainres.2008.02.032
Serra D, Almeida LM, Dinis TC (2016) Anti-inflammatory protection afforded by cyanidin-3-glucoside and resveratrol in human intestinal cells via Nrf2 and PPAR-gamma: comparison with 5-aminosalicylic acid. Chem Biol Interact 260:102–109. doi:10.1016/j.cbi.2016.11.003
Shimazu T et al (2005) A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36:353–359. doi:10.1161/01.STR.0000152271.21943.a2
Sivarajah A, McDonald MC, Thiemermann C (2005) The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-gamma antagonist. J Pharmacol Exp Ther 313:896–901. doi:10.1124/jpet.104.080598
Sobrado M et al (2009) Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J Neurosci 29:3875–3884. doi:10.1523/JNEUROSCI.5529-08.2009
Sohn W, Jun DW, Lee KN, Lee HL, Lee OY, Choi HS, Yoon BC (2015) Lactobacillus paracasei induces M2-dominant Kupffer Cell Polarization in a mouse model of nonalcoholic steatohepatitis. Dig Dis Sci 60:3340–3350. doi:10.1007/s10620-015-3770-1
Sood V, Colleran K, Burge MR (2000) Thiazolidinediones: a comparative review of approved uses. Diabetes Technol Ther 2:429–440
Speca S et al (2016) Novel PPARgamma Modulator GED-0507-34 Levo Ameliorates Inflammation-driven Intestinal Fibrosis. Inflamm Bowel Dis 22:279–292. doi:10.1097/MIB.0000000000000618
Sundararajan S, Landreth GE (2004) Antiinflammatory properties of PPARgamma agonists following ischemia. Drug News Perspect 17:229–236
Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE (2005) Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130:685–696. doi:10.1016/j.neuroscience.2004.10.021
Tan L, Yu JT, Guan HS (2008) Resveratrol exerts pharmacological preconditioning by activating PGC-1alpha. Med Hypotheses 71:664–667. doi:10.1016/j.mehy.2008.06.031
Thal SC, Neuhaus W (2014) The blood-brain barrier as a target in traumatic brain injury treatment. Arch Med Res 45:698–710. doi:10.1016/j.arcmed.2014.11.006
Thal SC, Heinemann M, Luh C, Pieter D, Werner C, Engelhard K (2011) Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-gamma-independent mechanisms. J Neurotrauma 28:983–993. doi:10.1089/neu.2010.1685
Tontonoz P, Spiegelman BM (2008) Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77:289–312. doi:10.1146/annurev.biochem.77.061307.091829
Tureyen K, Kapadia R, Bowen KK, Satriotomo I, Liang J, Feinstein DL, Vemuganti R (2007) Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 101:41–56. doi:10.1111/j.1471-4159.2006.04376.x
Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S (2011) The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res 2:236–240. doi:10.4103/2231-4040.90879
Uryu S, Harada J, Hisamoto M, Oda T (2002) Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Brain Res 924:229–236
Victor NA et al (2006) Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur J Neurosci 24:1653–1663. doi:10.1111/j.1460-9568.2006.05037.x
Villapol S, Saavedra JM (2015) Neuroprotective effects of Angiotensin receptor blockers. Am J Hypertens 28:289–299. doi:10.1093/ajh/hpu197
Villapol S, Yaszemski AK, Logan TT, Sanchez-Lemus E, Saavedra JM, Symes AJ (2012) Candesartan, an angiotensin II AT(1)-receptor blocker and PPAR-gamma agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. Neuropsychopharmacology 37:2817–2829. doi:10.1038/npp.2012.152
Villapol S, Balarezo MG, Affram K, Saavedra JM, Symes AJ (2015) Neurorestoration after traumatic brain injury through angiotensin II receptor blockage. Brain 138:3299–3315. doi:10.1093/brain/awv172
Wada K et al (2006) Peroxisome proliferator-activated receptor gamma-mediated regulation of neural stem cell proliferation and differentiation. J Biol Chem 281:12673–12681. doi:10.1074/jbc.M513786200
Wan Ibrahim WN, Tofighi R, Onishchenko N, Rebellato P, Bose R, Uhlen P, Ceccatelli S (2013) Perfluorooctane sulfonate induces neuronal and oligodendrocytic differentiation in neural stem cells and alters the expression of PPARgamma in vitro and in vivo. Toxicol Appl Pharmacol 269:51–60. doi:10.1016/j.taap.2013.03.003
Wang H et al (2009) Skeletal muscle-specific deletion of lipoprotein lipase enhances insulin signaling in skeletal muscle but causes insulin resistance in liver and other tissues. Diabetes 58:116–124. doi:10.2337/db07-1839
Wang Y et al (2016) Probiotic Lactobacillus casei Zhang reduces pro-inflammatory cytokine production and hepatic inflammation in a rat model of acute liver failure. Eur J Nutr 55:821–831. doi:10.1007/s00394-015-0904-3
White AT, Murphy AN (2010) Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review. J Neurochem 115:845–853. doi:10.1111/j.1471-4159.2010.06999.x
Woodcock T, Morganti-Kossmann MC (2013) The role of markers of inflammation in traumatic brain injury. Front Neurol 4:18. doi:10.3389/fneur.2013.00018
Xiong Y, Mahmood A, Chopp M (2009) Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs 14:67–84. doi:10.1517/14728210902769601
Yamakawa K, Hosoi M, Koyama H, Tanaka S, Fukumoto S, Morii H, Nishizawa Y (2000) Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 271:571–574. doi:10.1006/bbrc.2000.2665
Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R (2008) PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res 1244:164–172. doi:10.1016/j.brainres.2008.09.074
Yonutas HM, Sullivan PG (2013) Targeting PPAR isoforms following CNS injury. Curr Drug Targets 14:733–742
Yuan G, Chen X, Li D (2015) Modulation of peroxisome proliferator-activated receptor gamma (PPAR gamma) by conjugated fatty acid in obesity and inflammatory bowel disease. J Agric Food Chem 63:1883–1895. doi:10.1021/jf505050c
Zarzuelo MJ et al (2013) SIRT1 inhibits NADPH oxidase activation and protects endothelial function in the rat aorta: implications for vascular aging. Biochem Pharmacol 85:1288–1296. doi:10.1016/j.bcp.2013.02.015
Zeng Y, Xie K, Dong H, Zhang H, Wang F, Li Y, Xiong L (2012) Hyperbaric oxygen preconditioning protects cortical neurons against oxygen-glucose deprivation injury: role of peroxisome proliferator-activated receptor-gamma. Brain Res 1452:140–150. doi:10.1016/j.brainres.2012.02.063
Zeng XC, Li XS, Wen H (2013) Telmisartan protects against microvascular dysfunction during myocardial ischemia/reperfusion injury by activation of peroxisome proliferator-activated receptor gamma. BMC Cardiovasc Disord 13:39. doi:10.1186/1471-2261-13-39
Zhang Q, Hu W, Meng B, Tang T (2010) PPARgamma agonist rosiglitazone is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats. Neurol Res 32:852–859. doi:10.1179/016164110X12556180206112
Zhao Y, Patzer A, Gohlke P, Herdegen T, Culman J (2005) The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur J Neurosci 22:278–282. doi:10.1111/j.1460-9568.2005.04200.x
Zhao Y, Patzer A, Herdegen T, Gohlke P, Culman J (2006) Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 20:1162–1175. doi:10.1096/fj.05-5007com
Zhao W, Payne V, Tommasi E, Diz DI, Hsu FC, Robbins ME (2007) Administration of the peroxisomal proliferator-activated receptor gamma agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment. Int J Radiat Oncol Biol Phys 67:6–9. doi:10.1016/j.ijrobp.2006.09.036
Acknowledgements
This work was supported by R03NS095038 (SV) from the National Institute for Neurological Disorders and Stroke (NINDS), and by the Department of Neuroscience at Georgetown University Medical Center.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares no conflict of interest for this manuscript.
Rights and permissions
About this article
Cite this article
Villapol, S. Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation. Cell Mol Neurobiol 38, 121–132 (2018). https://doi.org/10.1007/s10571-017-0554-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-017-0554-5